BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

472 related articles for article (PubMed ID: 12729864)

  • 1. Aripiprazole in the treatment of schizophrenia: safety and tolerability in short-term, placebo-controlled trials.
    Marder SR; McQuade RD; Stock E; Kaplita S; Marcus R; Safferman AZ; Saha A; Ali M; Iwamoto T
    Schizophr Res; 2003 Jun; 61(2-3):123-36. PubMed ID: 12729864
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Aripiprazole: a review of its use in schizophrenia and schizoaffective disorder.
    Swainston Harrison T; Perry CM
    Drugs; 2004; 64(15):1715-36. PubMed ID: 15257633
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of aripiprazole and haloperidol versus placebo in patients with schizophrenia and schizoaffective disorder.
    Kane JM; Carson WH; Saha AR; McQuade RD; Ingenito GG; Zimbroff DL; Ali MW
    J Clin Psychiatry; 2002 Sep; 63(9):763-71. PubMed ID: 12363115
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The acute efficacy of aripiprazole across the symptom spectrum of schizophrenia: a pooled post hoc analysis from 5 short-term studies.
    Janicak PG; Glick ID; Marder SR; Crandall DT; McQuade RD; Marcus RN; Eudicone JM; Assunção-Talbott S
    J Clin Psychiatry; 2009 Jan; 70(1):25-35. PubMed ID: 19192472
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The efficacy, safety, and tolerability of aripiprazole for the treatment of schizoaffective disorder: results from a pooled analysis of a sub-population of subjects from two randomized, double-blind, placebo-controlled, pivotal trials.
    Glick ID; Mankoski R; Eudicone JM; Marcus RN; Tran QV; Assunção-Talbott S
    J Affect Disord; 2009 May; 115(1-2):18-26. PubMed ID: 19230981
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Aripiprazole, an antipsychotic with a novel mechanism of action, and risperidone vs placebo in patients with schizophrenia and schizoaffective disorder.
    Potkin SG; Saha AR; Kujawa MJ; Carson WH; Ali M; Stock E; Stringfellow J; Ingenito G; Marder SR
    Arch Gen Psychiatry; 2003 Jul; 60(7):681-90. PubMed ID: 12860772
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of akathisia in patients with schizophrenia, schizoaffective disorder, or bipolar I disorder: a post hoc analysis of pooled data from short- and long-term aripiprazole trials.
    Kane JM; Barnes TR; Correll CU; Sachs G; Buckley P; Eudicone J; McQuade R; Tran QV; Pikalov A; Assunção-Talbott S
    J Psychopharmacol; 2010 Jul; 24(7):1019-29. PubMed ID: 20008446
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A multicenter, randomized, double-blind, placebo-controlled, 16-week study of adjunctive aripiprazole for schizophrenia or schizoaffective disorder inadequately treated with quetiapine or risperidone monotherapy.
    Kane JM; Correll CU; Goff DC; Kirkpatrick B; Marder SR; Vester-Blokland E; Sun W; Carson WH; Pikalov A; Assunção-Talbott S
    J Clin Psychiatry; 2009 Oct; 70(10):1348-57. PubMed ID: 19906340
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intramuscular aripiprazole for the treatment of acute agitation in patients with schizophrenia or schizoaffective disorder: a double-blind, placebo-controlled comparison with intramuscular haloperidol.
    Andrezina R; Josiassen RC; Marcus RN; Oren DA; Manos G; Stock E; Carson WH; Iwamoto T
    Psychopharmacology (Berl); 2006 Oct; 188(3):281-92. PubMed ID: 16953381
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Aripiprazole alone or in combination for acute mania.
    Brown R; Taylor MJ; Geddes J
    Cochrane Database Syst Rev; 2013 Dec; (12):CD005000. PubMed ID: 24346956
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A multiple-center, randomized, double-blind, placebo-controlled study of oral aripiprazole for treatment of adolescents with schizophrenia.
    Findling RL; Robb A; Nyilas M; Forbes RA; Jin N; Ivanova S; Marcus R; McQuade RD; Iwamoto T; Carson WH
    Am J Psychiatry; 2008 Nov; 165(11):1432-41. PubMed ID: 18765484
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Symptomatic remission in schizophrenia patients treated with aripiprazole or haloperidol for up to 52 weeks.
    Kane JM; Crandall DT; Marcus RN; Eudicone J; Pikalov A; Carson WH; Swyzen W
    Schizophr Res; 2007 Sep; 95(1-3):143-50. PubMed ID: 17644313
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of aripiprazole vs. haloperidol for long-term maintenance treatment following acute relapse of schizophrenia.
    Kasper S; Lerman MN; McQuade RD; Saha A; Carson WH; Ali M; Archibald D; Ingenito G; Marcus R; Pigott T
    Int J Neuropsychopharmacol; 2003 Dec; 6(4):325-37. PubMed ID: 14609439
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Aripiprazole in schizophrenia and schizoaffective disorder: A review.
    Stip E; Tourjman V
    Clin Ther; 2010; 32 Suppl 1():S3-20. PubMed ID: 20152550
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adjunctive treatment with a dopamine partial agonist, aripiprazole, for antipsychotic-induced hyperprolactinemia: a placebo-controlled trial.
    Shim JC; Shin JG; Kelly DL; Jung DU; Seo YS; Liu KH; Shon JH; Conley RR
    Am J Psychiatry; 2007 Sep; 164(9):1404-10. PubMed ID: 17728426
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of aripiprazole in the acute treatment of schizophrenia in Chinese patients with risperidone as an active control: a randomized trial.
    Chan HY; Lin WW; Lin SK; Hwang TJ; Su TP; Chiang SC; Hwu HG
    J Clin Psychiatry; 2007 Jan; 68(1):29-36. PubMed ID: 17284127
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of oral aripiprazole compared with haloperidol in patients transitioning from acute treatment with intramuscular formulations.
    Daniel DG; Currier GW; Zimbroff DL; Allen MH; Oren D; Manos G; McQuade R; Pikalov AA; Crandall DT
    J Psychiatr Pract; 2007 May; 13(3):170-7. PubMed ID: 17522560
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Aripiprazole for the prevention of relapse in stabilized patients with chronic schizophrenia: a placebo-controlled 26-week study.
    Pigott TA; Carson WH; Saha AR; Torbeyns AF; Stock EG; Ingenito GG;
    J Clin Psychiatry; 2003 Sep; 64(9):1048-56. PubMed ID: 14628980
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of aripiprazole against hostility in schizophrenia and schizoaffective disorder: data from 5 double-blind studies.
    Volavka J; Czobor P; Citrome L; McQuade RD; Carson WH; Kostic D; Hardy S; Marcus R
    J Clin Psychiatry; 2005 Nov; 66(11):1362-6. PubMed ID: 16420071
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term efficacy and safety of aripiprazole in patients with schizophrenia, schizophreniform disorder, or schizoaffective disorder: 26-week prospective study.
    Kwon JS; Jang JH; Kang DH; Yoo SY; Kim YK; Cho SJ;
    Psychiatry Clin Neurosci; 2009 Feb; 63(1):73-81. PubMed ID: 19154213
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.